BPC-157: Deep Animal Record, Thin Human File

The short version

BPC-157 — Body Protection Compound 157 — is a synthetic peptide of fifteen amino acids copied from part of a protective protein found in human stomach juice. In animal studies, predominantly in rats, it appears to accelerate healing across a wide range of tissues: tendons, the gut lining, muscle and nerve. The most consistently supported explanation is that it helps the body grow new blood vessels into the injury site, delivering the oxygen and nutrients that repair requires ^[10].

The honest qualification: almost all of this evidence is in animals. As of 2025 reviews, only three small human pilot studies exist, and no large rigorous human trials have been run ^[9]. BPC-157 is not an approved drug anywhere; it is banned in sport; and common online claims about weight loss or muscle building are not supported by the published science ^[9]. This page summarizes what was studied. It is not advice, and it lists no human dose.

What it is

BPC-157 is a stable gastric pentadecapeptide — fifteen amino acids, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (C62H98N16O22). "Stable gastric" means the sequence originates from a cytoprotective protein in gastric juice and resists breakdown in the stomach. It is also catalogued under research designations PL 14736, PLD-116, PL-10, and Bepecin. It is a synthetic research peptide, not extractable from a natural source, and holds no approved drug status in any major jurisdiction.

How it works

The best-characterized mechanism is angiogenesis — the formation of new blood vessels. In work spanning a chick chorioallantoic membrane model, rat hindlimb ischemia, and human vascular endothelial cells, BPC-157 increased expression and promoted internalization of the VEGFR2 receptor, activating the downstream VEGFR2-Akt-eNOS pathway; blocking internalization blocked the effect ^[10]. In plain terms: it appears to make blood-vessel cells more responsive to the body's own vessel-growth signal, and it accelerated blood-flow recovery in a blocked-circulation muscle model ^[10].

Additional reported mechanisms include FAK-paxillin (cell migration), growth-hormone-receptor sensitization in tendon fibroblasts, Egr-1/NAB2 and JAK-2 signaling, and modulation of serotonin and dopamine systems in the brain-gut axis. The throughline is a peptide that nudges several repair-related signals in parallel rather than a single target.

What the research shows

First-in-human safety pilot. Intravenous BPC-157 up to 20 mg in two healthy adults was well tolerated with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers. This was a tiny n=2; not an efficacy trial ^[2].

Human evidence overview. A 2025 narrative review states that only three pilot studies have examined BPC-157 in humans, that rigorous large-scale trials are lacking, and recommends treating BPC-157 as investigational and using it with caution given regulatory controversy and non-regulated availability ^[9].

Pharmacokinetics. The first formal PK/ADME characterization found linear pharmacokinetics, a very short elimination half-life (under 30 minutes), modest intramuscular bioavailability (~14-19% in rats, ~45-51% in dogs), and rapid breakdown into small peptide fragments re-entering normal amino-acid metabolism ^[12]. The intact peptide does not linger in the bloodstream.

Angiogenesis mechanism. BPC-157 upregulated VEGFR2 expression, promoted VEGFR2 internalization and activated the downstream VEGFR2-Akt-eNOS pathway, increasing vessel density in vivo and in vitro and accelerating blood-flow recovery in ischemic muscle; blocked by endocytosis inhibition ^[10].

Gut. Foundational cytoprotection study: BPC-157 reduced gastric ulcer area and accelerated ulcer healing in Wistar rats, with intramuscular delivery outperforming intragastric; ulcer-formation inhibition ratios of 45.7-65.6% at higher doses; accelerated glandular-epithelium rebuilding and granulation-tissue formation ^[13].

Tendon. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic and macroscopic measures, stimulated tendocyte outgrowth in culture, and improved collagen organization and tendon integrity versus untreated controls ^[6].

Reported effects, cautions & safety

No community-anecdote signals are compiled in this desk's source material for BPC-157 as a standalone. The following cautions come from the cited literature.

• Evidence is overwhelmingly preclinical. Most data come from rodents. A large share of the foundational literature originates from a single research group, which newer reviews explicitly flag as raising independent-replication questions ^[9].
• Regulatory status. BPC-157 is not an approved drug anywhere and is widely distributed through non-regulated channels; product identity, purity and dose are unverified outside formal studies. In 2023 the FDA placed it in a category of substances not eligible for pharmacy compounding under 503A pending further evaluation ^[9].
• WADA prohibition. Prohibited in sport at all times under the S0 non-approved-substances category ^[1].
• Short half-life. The very short elimination half-life (under 30 minutes) means the intact peptide clears quickly; community "loading" rationales have no basis in controlled human PK data ^[12].
• Safety profile unknown. The 2025 first-in-human pilot is two people; there are no long-term large-sample human safety data ^[2][9].

Where it fits in recovery research

BPC-157 is the most individually studied single component on this desk and one of the two components of Wolverine and all four components of KLOW. Its animal record is broad — tendon, gut, muscle, nerve — unified by an angiogenesis-forward mechanism. Its human file is three small pilots. Alongside TB-500, which approaches repair through actin-driven cell migration, BPC-157 illustrates the central tension in this field: a coherent, multi-decade preclinical signal that has barely crossed into controlled human work. See the comparison page for the side-by-side.